Overview

• Lilly will invest $6.5 billion in the Houston site as one of four new U.S. plants backed by at least $27 billion, with medicine production expected across all four within five years.
• The facility will produce active ingredients for orforglipron, a daily oral GLP‑1 candidate, along with other small‑molecule medicines spanning cardiometabolic disease, oncology, immunology and neuroscience.
• The project is expected to create about 615 permanent skilled jobs in Greater Houston and roughly 4,000 construction roles.
• Late‑stage data showed orforglipron led to about 12.4% average weight loss, and Lilly plans to submit the drug for regulatory review later this year.
• CEO David Ricks said the plant will be a major hub for scaling orforglipron production, with additional manufacturing also planned in Indiana, and cited Texas’ chemical‑engineering talent as a key reason for the location.